PTO/SB/05 (01-04)

Approved for use through 07/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION **TRANSMITTAL**

Attorney Docket No. 1735.0870001/RWE/ALS First Inventor Shailaja Kasibhatla See 1 in Addendum Title

(Only for new nonprovisional applications under 37 CFR 1.53(b))	Express Mail Label No.
APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.	ADDRESS TO: Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450
1.	7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix) 8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. X Computer Readable Form (CRF) b. Specification Sequence Listing on: i. CD-ROM or CD-R (2 copies); or ii. X Paper c. X Statements verifying identity of above copies ACCOMPANYING APPLICATION PARTS 9. Assignment Papers (cover sheet & document(s)) 10. 37 CFR 3.73(b) Statement Power of (when there is an assignee) Attorney 11. English Translation Document (if applicable) 12. Information Disclosure Copies of IDS Statement (IDS)/PTO-1449 Citations 13. Preliminary Amendment 14. X Return Receipt Postcard (MPEP 503) (Should be specifically itemized) 15. Certified Copy of Priority Document(s) (if foreign priority is claimed) 16. Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent. 17. X Other: Authorization under 37CFR 1.136(a)(3)
18. If a CONTINUING APPLICATION, check appropriate box, and sup	ply the requisite information below and in the first sentence of the
specification following the title, or in an Application Data Sheet under 37 CFR 1.76: Continuation Divisional Continuation-in-part (CIP) of prior application No.:	
For CONTINUATION OF DIVISIONAL APPS only; The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.	
19. CORRESPONDENCE ADDRESS	
X Customer Number: 26111	OR Correspondence address below
Name Aaron L. Schwartz	
Address	
City	State Zip Code
	elephone Fax
Name (Print/Type) Aaron L. Schwartz	Registration No. (Attorney/Agent) 48,181
Signature This collection of information is required by 27 CER 1 52(b). The information is required by 27 CER 1 52(b). The information is required by 27 CER 1 52(b).	Date April 19, 2004

This collection of information is required by 37 CFR 1.53(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.O. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Addendum

 Methods Of Treating Diseases Responsive To Induction Of Apoptosis And Screening Assays

APR 19 7004 SEE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Kasibhatla et al.

Appl. No.: (to be assigned)

Filed: (herewith)

For: Methods of Treating Diseases
Responsive to Induction of
Apoptosis and Screening Assays

Confirmation No.: (to be assigned)

Art Unit: (to be assigned)

Examiner: (to be assigned)

Atty. Docket: 1735.0870001/RWE/ALS

Authorization to Treat a Reply as Incorporating an Extension of Time Under 37 C.F.R. § 1.136(a)(3)

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Mail Stop Patent Application

Sir:

The U.S. Patent and Trademark Office is hereby authorized to treat any concurrent or future reply that requires a petition for an extension of time under this paragraph for its timely submission, as incorporating a petition for extension of time for the appropriate length of time. The U.S. Patent and Trademark Office is hereby authorized to charge all required extension of time fees to our Deposit Account No. 19-0036, if such fees are not otherwise provided for in such reply.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Agent for Applicants Registration No. 48,181

Date: <u>April 19, 2004</u>

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600

254342_1.DOC



Robert Greene Sterne Edward J. Kessler Jorge A. Goldstein David K.S. Cornwell Robert W. Esmond Tracy-Gene G. Durkin Michaele A. Cimbala Michael B. Ray Robert E. Sokohl Eric K. Steffe Michael Q. Lee Steven R. Ludwig John M. Covert Linda E. Alcorn Robert C. Millonig Donald J. Featherstone Lawrence B. Bugaisky Michael V. Messinger Judith U. Kim Ilmothy J. Shea, Jr. Patrick E. Garrett Heidi L. Kraus Edward W. Yee Albert L. Ferro* Oonald R. Banowit Peter A. Jackman Ieresa U. Medler Jeffrey S. Weaver Kendrick P. Patterson Vincent L. Capunas Eldora Ellison Floyd Thomas C. Fiala Brian J. Del Buono Virgil Lee Beaston Kimberly N. Reddick Heodore A. Wood Elizabeth J. Haanes Joseph S. Ostroff Frank R. Cottingham Christine M. Lhulier Rea Lynn Prengaman Jane Shershenovich' George S. Bardmesser Daniel A. Klein' Jason D. Eisenberg Michael D. Specht Andrea J. Kamage Tracy L. Muller' LwAnne M. DeSantis John J. Figueroa Ann E. Summerfield Tiera S. Coston Aric W. Ledford' Jessica L. Parezo Timothy A. Doyle*
Gaby L. Longsworth*
Nicole D. Dretar*
Ted J. Ebersole
Jyoti C. Iyer*

Registered Patent Agent
Karen R. Markowicz
Nancy J. Leith
Hebers C. Gardon

Registered Patent Agents-Karen R. Markowicz Nancy J. Leith Helene C. Carlson Matthew J. Dowd Aaron L. Schwartz Katrina Y. Pei Quach Bryan L. Skelton Robert A. Schwartzman Teresa A. Colella Jeffrey S. Lundgren Victoria S. Rutherford

Mail Stop Patent Application

Eric D. Hayes Michelle K. Holoubek Robert H. DeSelms Simon J. Elliott Julie A. Heider Mita Mukherjee Scott M. Woodhouse

Of Counsel Kenneth C. Bass III Evan R. Smith Marvin C. Guthrie

*Admitted only in Maryland * Admitted only in Virginia • Practice Limited to Federal Agencies

April 19, 2004

WRITER'S DIRECT NUMBER: (202) 772-8619 INTERNET ADDRESS: SCHWARTZ@SKGF.COM

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Re:

U.S. Non-Provisional Utility Patent Application under 37 C.F.R. § 1.53(b)

Appl. No. (to be assigned); filed (herewith)

For:

Methods of Treating Diseases Responsive to Induction of

Apoptosis and Screening Assays

Inventors:

Kasibhatla et al.

Our Ref:

1735.0870001/RWE/ALS

Sir:

The following documents are forwarded herewith for appropriate action by the U.S. Patent and Trademark Office:

- 1. PTO Utility Patent Application Transmittal (Form PTO/SB/05);
- 2. Authorization to Treat a Reply As Incorporating An Extension of Time Under 37 C.F.R. § 1.136(a)(3);
- 3. U.S. Utility Patent Application entitled:

Methods of Treating Diseases Responsive to Induction of Apoptosis and Screening Assays

and naming as inventors:

Shailaja Kasibhatla, Sui Xiong Cai, Ben Tseng, Katayoun Alavi Jessen, Serguei Maliartchouk, Nicole Marion English, Jared Kuemmerle, William E. Kemnitzer and Han-Zhong Zhang

the application consisting of:

a. an Application Data Sheet (37 C.F.R. § 1.76):

Sterne, Kessler, Goldstein & Fox PLLC. : 1100 New York Avenue, NW: Washington, DC 20005: 202.371.2600 f 202.371.2540: www.skgf.com

Commissioner for Patents April 19, 2004 Page 2

- b. specification containing:
 - i. 113 pages of description prior to the claims;
 - ii. 6 pages of claims (claims 1-32);
 - iii. 1 page abstract;
- c. Three (3) sheets of drawings (Figures 1a-1b; 2 and 3a-3c);
- d. Thirty-four (34) pages of paper copy of sequence listing; and
- e. A computer readable copy of the sequence listing. In accordance with 37 C.F.R. § 1.821(f), the paper copy of the sequence listing and the computer readable copy of the sequence listing submitted herewith in the above application are the same; and
- 4. Two (2) return postcards.

Applicant claims small entity status (37 C.F.R. § 1.27).

Correspondence should be sent to Customer Number 26111.

It is respectfully requested that, of the two attached postcards, one be stamped with the filing date of these documents and returned to our courier, and the other, prepaid postcard, be stamped with the filing date and unofficial application number and returned as soon as possible.

This patent application is being submitted under 37 C.F.R. § 1.53(b) without Declaration and without filing fee.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Aaron L. Schwartz

Agent for Applicants

Registration No. 48,181

ALS/dab 254332_1.DOC Enclosures